InsidersTradesSigma
Follow the Ayala Pharmaceuticals, Inc. share price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Health Care sector, Ayala Pharmaceuticals, Inc. has published 8 insider filings. Market capitalisation: €1,096.4bn. The latest transaction was filed on 12 February 2024 (Levée d'options). Among the most active insiders: Israel Biotech Fund I, L.P.. The full history is accessible without an account.
8
Insider Decl.
n/a
Thresholds
n/a
2 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Ayala Pharmaceuticals, Inc. Strong Buy (bullish), based on 42 analysts. Average price target: US$1,491.95.
23Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 3,842 of 29,064 companies
71.3
score / 100
Value64
Quality79
FCF yld1.2%
Earn yld6.4%
EV/EBITDA8.1x
ROE67%
Gross mgn40%
Net mgn23%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 12 February 2024
Declarations8 total
1,926,221 shares@ US$0.40100.0% of flowCommon Stock, par value $0.001 per shareSEC:0001178913-24-000480:0
658,858 shares0Common Stock, par value $0.001 per shareSEC:0001178913-23-003462:0
Canonical exit: 16 Jan 2024 (T+90)
658,858 shares0Common Stock, par value $0.001 per shareSEC:0001178913-23-003462:1
Canonical exit: 16 Jan 2024 (T+90)
00Common StockSEC:0001178913-23-003362:0
46 sharesCommon StockSEC:0001493152-23-002246:0
50,000 shares0Common StockSEC:0000899243-22-018134:0
120,000 shares0Common StockSEC:0000899243-22-018133:0
50,000 shares0Common StockSEC:0000899243-22-018135:0
8 of 8 declarations
关于 Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc. 是一家生物制药公司，专注于开发罕见癌症和遗传疾病的疗法。该公司在纳斯达克上市，股票代码为 AYLA。